WALTHAM, Mass.--(BUSINESS WIRE)-- Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as one of the most promising biotech companies in the industry.
An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position.
“Better protein silencing technology can create better, longer acting therapies, and Avila Therapeutics thinks it has the inside track on developing new drugs that create durable bonds with their targets. Lots and lots of targets,” says John Carroll, editor of FierceBiotech. “Like others on this year’s aggressive Fierce 15 list, Avila isn’t waiting until it has mid-stage data in hand to start talking deals. It is relying on an innovative platform technology to move fast on new pacts to identify new drug candidates -- inking deals and generating revenue before its lead drug ever hit the clinic.”
Avila is designing and developing targeted covalent drugs to achieve best-in-class outcomes that cannot be achieved through traditional chemistries. The company’s product pipeline has been built using its proprietary Avilomics™ platform and is currently focused on cancer, autoimmune disease, and hepatitis C infection. Avila’s wholly-owned lead program, which targets Bruton’s tyrosine kinase (Btk), is on track to enter clinical development this year. The company has also established collaborations with the Novartis Option Fund, with the Leukemia & Lymphoma Society, and with Clovis Oncology across a number of distinct programs.
"Being selected as a member of the 'Fierce 15' is a validation of the progress we have made and the opportunity we have with our platform and the unique profiles of our targeted covalent drugs," said Katrine Bosley, Chief Executive Officer of Avila. "Our covalent drugs have exceptional therapeutic benefits as they solve the critical therapeutic challenges of precisely inhibiting specific difficult targets and addressing resistance mutations. We are looking forward to entering the clinic later this year to demonstrate these benefits with our lead program targeting Bruton's tyrosine kinase.”
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. A complete list of “Fierce 15” companies is available online at www.fiercebiotech.com.
FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 75,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Sign up is free at http://www.fiercebiotech.com.
About Avila Therapeutics
Avila focuses on design and development of targeted covalent drugs to achieve best-in-class outcomes that cannot be achieved through traditional chemistries. This approach is called “protein silencing”. The company’s product pipeline has been built using its proprietary Avilomics™ platform and is currently focused on cancer, autoimmune disease, and hepatitis C infection. Avila is funded by leading venture capital firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. For additional information, please visit http://www.avilatx.com.
The Yates Network
Kathryn Morris, 845-635-9828
Heather Cox Martin, 202-824-5043
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical